GH Research PLC

GHRS

13.030USD

-0.390-2.91%

Market hours （ET）Quotes delayed by 15 min

Score

Industry at a Glance

Industry Ranking

227 / 686

Overall Ranking

357 / 4730

Industry

Pharmaceuticals & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 8 analysts

Buy

Current Rating

31.667

Target Price

+134.39%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 73.50.

Undervalued

The company’s latest PE is -18.21, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 63.73M shares, increasing 10.09% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 0.00 shares of this stock.

There is no financial score for this company; the Pharmaceuticals & Medical Research industry's average is 6.80.

Score

Industry at a Glance

Previous score

0.00

Change

0



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals & Medical Research industry's average of 1.64. Its current P/E ratio is -18.50, which is -26.73% below the recent high of -13.55 and 7.03% above the recent low of -17.20.

Score

Industry at a Glance

Previous score

1.20

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 227/686

No Data

The company’s current earnings forecast score is 8.50, which is higher than the Pharmaceuticals & Medical Research industry's average of 7.96. The average price target for GH Research PLC is 32.00, with a high of 40.00 and a low of 25.00.

Score

Industry at a Glance

Previous score

8.50

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 8.76, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 15.15 and the support level at 11.72, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.74

Change

-1.41

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated：2025-09-09

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.02. The latest institutional shareholding proportion is 102.74%, representing a quarter-over-quarter decrease of 0.02%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Schonharting (Florian)

14.82M

--

BVF Partners L.P.

8.83M

-15.12%

RA Capital Management, LP

6.94M

+3.86%

Lynx1 Capital Advisors LLC

6.44M

+1.43%

RTW Investments L.P.

5.50M

+65.30%

Fidelity Management & Research Company LLC

4.25M

+70.85%

Terwey (Theis)

6.19M

--

Cormorant Asset Management, LP

2.01M

+238.84%

Deep Track Capital LP

2.00M

--

TD Securities, Inc.

1.97M

--



1

2



The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Pharmaceuticals & Medical Research mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 3.23, which is lower than the Pharmaceuticals & Medical Research industry's average of 3.51. The company's beta value is 0.97. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

GH Research PLC

GHRS

4.67 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Royalty Pharma PLC

RPRX

7.72 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Neurocrine Biosciences Inc

NBIX

7.65 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Stoke Therapeutics Inc

STOK

7.56 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

7.46 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Protagonist Therapeutics Inc

PTGX

7.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.